Live feed07:01:00·616dPRReleasevia QuantisnowViiV Healthcare Shows More Than 99% Effectiveness in Real-World Studies for Apretude (Cabotegravir Long-Acting), the Only Approved Long-Acting HIV PrEP, in Data Presented at IDWeek 2024ByQuantisnow·Wall Street's wire, on your screen.PFE· Pfizer Inc.Health Care
